Extending Life with Hyperbaric Oxygen Therapy

Who Benefits?Schedule an Appointment

Extending Life with Hyperbaric Oxygen Therapy

Who Benefits?Schedule an Appointment

Hyperbaric Oxygen Therapy at Extivita

Hyperbaric Oxygen Therapy, also known as HBOT involves breathing 100% oxygen in a pressurized chamber to increase oxygen levels in blood plasma. A century of clinical research has shown that increased oxygen in plasma accelerates our natural ability to heal through neurogenesis and angiogenesis. In addition, HBOT upregulates over 8000 anti-inflammatory genes and activates the release of stem cells and growth factors associated with the body’s regenerative and reparative processes.

Globally, HBOT is used to extend and improve quality of life by augmenting the treatment of all injuries, diseases, and infections as well as to improve overall wellness and the physical performance of athletes.

Personalized Treatments

Unique treatment plans created for patients suffering from a variety of conditions

Scientifically Proven

Used in hospitals and clinics around the world

HBOT Treatments

Reduce inflammation and enhance the body’s natural ability to heal

Professional Team

An experienced team of medical doctors and staff dedicated to your well-being

EXPLORING HBOT RESEARCH

Globally, Hyperbaric Oxygen Therapy is used to extend and improve quality of life for patients by augmenting the treatment of all injuries, diseases, and infections as well as to improve overall wellness and the physical performance of athletes. Explore our research database to see if HBOT might be right for you!

Recent HBOT Research

Local doctor continues to push VA to approve Hyperbaric Oxygen Therapy for veterans

Local doctor continues to push VA to approve Hyperbaric Oxygen Therapy for veterans

The AC133 antigen is a novel antigen selectively expressed on a subset of CD34+ cells in human fetal liver, bone marrow, and blood as demonstrated by flow cytometric analyses. In this study, we have further assessed the expression of AC133 on CD34+ cells in hemopoietic samples and found that there was a highly significant difference between normal bone marrow and cord blood versus aphereses (p <0.0001) but not between bone marrow and cord blood. Most of the clonogenic cells (67%) were contained in the CD34+AC133+ fraction. Compared with cultures of the CD34+AC133- cells, generation of progenitor cells in long-term culture on bone marrow stroma was consistently 10- to 100-fold higher in cultures initiated with CD34+AC133+ cells and was maintained for the 8-10 weeks of culture.

Study Reveals Oxygen-Rich Air Can Reverse Severe Brain Damage

Study Reveals Oxygen-Rich Air Can Reverse Severe Brain Damage

The AC133 antigen is a novel antigen selectively expressed on a subset of CD34+ cells in human fetal liver, bone marrow, and blood as demonstrated by flow cytometric analyses. In this study, we have further assessed the expression of AC133 on CD34+ cells in hemopoietic samples and found that there was a highly significant difference between normal bone marrow and cord blood versus aphereses (p <0.0001) but not between bone marrow and cord blood. Most of the clonogenic cells (67%) were contained in the CD34+AC133+ fraction. Compared with cultures of the CD34+AC133- cells, generation of progenitor cells in long-term culture on bone marrow stroma was consistently 10- to 100-fold higher in cultures initiated with CD34+AC133+ cells and was maintained for the 8-10 weeks of culture.

Noninvasive Therapy that can help in a variety of medical conditions

Noninvasive Therapy that can help in a variety of medical conditions

Benefits of Hyperbaric Oxygen Therapy

Improves Circulation

Maximizes Oxygen Transport

Preserves, Repairs, & Enhances Cellular Functions

Increases Amount of Oxygen in the Blood

Accelerates Wound Healing

Prevents Further Cellular Damage

Reduces Inflammation & Swelling

Enhances Anti-Microbial Function

ABOUT OUR CLINIC

WE ARE MULTI-SEAT HYPERBARIC CHAMBER CLINIC

A multi-seat hyperbaric chamber is designed to treat multiple patients at a time. Patients sit in chairs while they receive oxygen through individual hoods while the chamber pressurizes to equivalent pressure of a shallow dive.

Recent HBOT News

Local doctor continues to push VA to approve Hyperbaric Oxygen Therapy for veterans

Local doctor continues to push VA to approve Hyperbaric Oxygen Therapy for veterans

The AC133 antigen is a novel antigen selectively expressed on a subset of CD34+ cells in human fetal liver, bone marrow, and blood as demonstrated by flow cytometric analyses. In this study, we have further assessed the expression of AC133 on CD34+ cells in hemopoietic samples and found that there was a highly significant difference between normal bone marrow and cord blood versus aphereses (p <0.0001) but not between bone marrow and cord blood. Most of the clonogenic cells (67%) were contained in the CD34+AC133+ fraction. Compared with cultures of the CD34+AC133- cells, generation of progenitor cells in long-term culture on bone marrow stroma was consistently 10- to 100-fold higher in cultures initiated with CD34+AC133+ cells and was maintained for the 8-10 weeks of culture.

Study Reveals Oxygen-Rich Air Can Reverse Severe Brain Damage

Study Reveals Oxygen-Rich Air Can Reverse Severe Brain Damage

The AC133 antigen is a novel antigen selectively expressed on a subset of CD34+ cells in human fetal liver, bone marrow, and blood as demonstrated by flow cytometric analyses. In this study, we have further assessed the expression of AC133 on CD34+ cells in hemopoietic samples and found that there was a highly significant difference between normal bone marrow and cord blood versus aphereses (p <0.0001) but not between bone marrow and cord blood. Most of the clonogenic cells (67%) were contained in the CD34+AC133+ fraction. Compared with cultures of the CD34+AC133- cells, generation of progenitor cells in long-term culture on bone marrow stroma was consistently 10- to 100-fold higher in cultures initiated with CD34+AC133+ cells and was maintained for the 8-10 weeks of culture.